Clinical Trials Directory

Trials / Completed

CompletedNCT00808327

Spinal Anesthesia for Cesarean Delivery: Bupivacaine With or Without Fentanyl

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
140 (actual)
Sponsor
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Academic / Other
Sex
Female
Age
16 Years – 50 Years
Healthy volunteers
Accepted

Summary

The safest form of anesthesia for Cesarean section is a spinal anesthetic. All spinal anesthetics contain a local anesthetic and/or a narcotic. A drug named bupivacaine is the most commonly used local anesthetic in spinal anesthetics for Cesarean deliveries in North America. Another drug named fentanyl is the most commonly used narcotic. This study will look at whether a spinal anesthetic with 15mg of bupivacaine alone will be the same as a spinal anesthetic with 12mg of bupivacaine and 15ug of fentanyl.

Detailed description

There have been many studies looking at different doses and combinations of bupivacaine and fentanyl but there is no agreement among anesthesiologists as to the best combination of drugs. The main problem with bupivacaine is that it causes hypotension (low blood pressure). When fentanyl is added to bupivacaine, a lower dose of bupivacaine can be used so that there is less of a fall in blood pressure. The main problem with fentanyl is itchiness and sleepiness. In the case of an emergency Cesarean section, the extra time needed to draw-up and administer a second medication may make a difference to the health of the baby. Our goal is to determine whether high dose bupivacaine (15mg) alone will produce spinal anaesthesia for cesarean delivery equivalent to 12mg of intrathecal hyperbaric bupivacaine in combination with 15ug of intrathecal fentanyl.

Conditions

Interventions

TypeNameDescription
DRUGBupivacaineA single, 15mg, intrathecal dose of bupivacaine.
DRUGBupivacaine, fentanylA single, 12 mg, intrathecal dose of bupivacaine, plus 15 micrograms of fentanyl

Timeline

Start date
2009-01-01
Primary completion
2009-08-01
Completion
2009-08-01
First posted
2008-12-15
Last updated
2009-11-20

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT00808327. Inclusion in this directory is not an endorsement.